Table of contents

Clinical/translational cancer immunotherapy

• Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis (28 February, 2024)

  Hironori Bando, Masaaki Yamamoto, Shin Urai, Yuma Motomura, Yuriko Sasaki, Yuka Ohmachi, Masaki Kobatake, Yasutaka Tsujimoto, Yuka Oi-Yo, Masaki Suzuki, Naoki Yamamoto, Michiko Takahashi, Hidenori Fukuoka, Genzo Iguchi, Wataru Ogawa
• Original research: Cardiovascular toxicities associated with bispecific T-cell engager therapy (21 February, 2024)

  Ahmed Sayed, Malak Munir, Sanam M Ghazi, Mussammat Ferdousi, Satyam Krishan, Adnan Shaaban, Alma Habib, Onaopepo Kola-Kehinde, Patrick Ruz, Sarah Khan, Sneha Sharma, Alexa Meara, Syed Mahmood, Stephanie Feldman, Eric H Yang, Jiwon Kim, Narendranath Epperla, Daniel Addison
• Original research: First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial (21 February, 2024)

  Shengxiang Ren, Xicheng Wang, Bao-Hui Han, Yueyin Pan, Jun Zhao, Yufeng Cheng, Sheng Hu, Tianshu Liu, Yalun Li, Ying Cheng, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Shegan Gao, Yongzhong Luo, Ying Liu, Caigang Liu, Huijie Duan, Shuni Wang, Xinfeng Yang, Jia Fan, Caicun Zhou
• Original research: Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial (12 February, 2024)

  David P. Carbone, Tudor-Eliade Ciuleanu, Michael Schenker, Manuel Cobo, Stéphanie Bordenave, Oscar Juan-Vidal, Juliana Menezes, Niels Reinmuth, Eduardo Richardet, Ying Cheng, Hideaki Mizutani, Enriqueta Felip, Bogdan Zurawski, Aurelia Alexandru, Luis Paz-Ares, Shun Lu, Thomas John, Xiaoqing Zhang, Javed Mahmood, Nan Hu, Tuli De, Irene Santi, John R. Penrod, Yong Yuan, Adam Lee, Martin Reck
• Original research: Multiomic molecular characterization of the response to combination immunotherapy in MSS/pMMR metastatic colorectal cancer (8 February, 2024)

  Shogo Takei, Yosuke Tanaka, Yi-Tzu Lin, Shohei Koyama, Shota Fukuoka, Hiroki Hara, Yoshiaki Nakamura, Yasutoshi Kuboki, Daisuke Kotani, Takashi Kojima, Hideaki Bando, Saori Mishima, Toshihide Ueno, Shinya Kojima, Masashi Wakabayashi, Naoya Sakamoto, Motohiro Kojima, Takeshi Kuwata, Takayuki Yoshino, Hiroyoshi Nishikawa, Hiroyuki Mano, Itaru Endo, Kohei Shitara, Akihito Kawazoe
• Original research: Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032) (5 February, 2024)

  Margaret Callahan, Asim Amin, Frederic J Kaye, Michael A Morse, Matthew H Taylor, Katriina J Peltola, Padmanee Sharma, Eileen M O'Reilly, Stephanie Meadows Shropshire, Shaun O'Brien, Marina Tschaika, Dung T Le
• Original research: Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors (2 February, 2024)

  Sandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, Ding Wang, Jarushka Naidoo, Nathan E Standifer, Doug C Palmer, Lin-Yang Cheng, Panagiotis Kourtesis, Maria L Ascierto, Mayukh Das, Jennifer R Diamond, Matthew D Hellmann, Benedito A Carneiro
• Original research:

  Salmonella-mediated methionine deprivation drives immune activation and enhances immune checkpoint blockade therapy in melanoma

  (1 February, 2024)

  Sujin Zhou, Shiwei Zhang, Kexin Zheng, Zixuan Li, Enyu Hu, Yunping Mu, Jialuo Mai, Allan Zhao, Zhenggang Zhao, Fanghong Li